Affordable Access

deepdyve-link
Publisher Website

Strongly enhanced levels of sclerostin during human fracture healing.

Authors
  • Sarahrudi, Kambiz
  • Thomas, Anita
  • Albrecht, Christian
  • Aharinejad, Seyedhossin
Type
Published Article
Journal
Journal of orthopaedic research : official publication of the Orthopaedic Research Society
Publication Date
Oct 01, 2012
Volume
30
Issue
10
Pages
1549–1555
Identifiers
DOI: 10.1002/jor.22129
PMID: 22508529
Source
Medline
License
Unknown

Abstract

Sclerostin (SOST), an antagonist of Wnt signaling, is an important negative regulator of bone formation. However, no data on the role of SOST in the human fracture healing have been published so far. This study addressed this issue. Seventy-five patients with long bone fractures were included into the study and divided in two groups. The first group contained 69 patients with normal fracture healing. Six patients with impaired fracture healing formed the second group. Thirty-four volunteers donated blood samples as control. Serum samples were collected over a period of 1 year following a standardized time schedule. In addition, SOST levels were measured in fracture hematoma and serum of 16 patients with bone fractures. Fracture hematoma contained significantly higher SOST concentrations compared to patient's serum. SOST levels in fracture hematoma and in patient's serum were both significantly higher than in the serum of controls. Highly elevated SOST serum concentrations were found in patients with physiological fracture healing. SOST levels were decreased in patients with impaired fracture healing. However, this difference was not statistically significant. This is the first study to provide evidence of strongly enhanced SOST levels in patients with bone fracture. The results indicate local and systemic involvement of SOST in humans during fracture healing.

Report this publication

Statistics

Seen <100 times